TAP1 sirna

TAP1 siRNA (Human)

Cat. Num. AAA8232002

• Gene Names: TAP1; APT1; PSF1; ABC17; ABCB2; PSF-1; RING4; TAP1N; D6S114E; TAP1*0102N
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: TAP1; TAP1 siRNA (Human); ABCB2; PSF1; RING4; Y3; Antigen peptide transporter 1; APT1; ATP-binding cassette sub-family B member 2; Peptide supply factor 1; Peptide transporter PSF1; PSF-1; Peptide transporter TAP1; Peptide transporter involved in antigen processing 1; Really interesting new gene 4 protein; TAP1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: TAP1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 808

• Applicable Applications for TAP1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human TAP1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for TAP1 sirna

siRNA to inhibit TAP1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 9665248
• NCBI GeneID: 6890
• NCBI Accession #: NP_000584.2
• NCBI GenBank Nucleotide #: NM_000593.5
• UniProt Accession #: Q03518; Q16149; Q96CP4
• Molecular Weight: 87,218 Da
• NCBI Official Full Name: antigen peptide transporter 1 isoform 1
• NCBI Official Synonym Full Names: transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
• NCBI Official Symbol: TAP1
• NCBI Official Synonym Symbols: APT1; PSF1; ABC17; ABCB2; PSF-1; RING4; TAP1N; D6S114E; TAP1*0102N
• NCBI Protein Information: antigen peptide transporter 1
• UniProt Protein Name: Antigen peptide transporter 1
• Protein Family: Protein
• UniProt Gene Name: TAP1
• UniProt Synonym Gene Names: ABCB2; PSF1; RING4; Y3; APT1; PSF-1
• UniProt Entry Name: TAP1_HUMAN

NCBI Description

The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is involved in the pumping of degraded cytosolic peptides across the endoplasmic reticulum into the membrane-bound compartment where class I molecules assemble. Mutations in this gene may be associated with ankylosing spondylitis, insulin-dependent diabetes mellitus, and celiac disease. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]

Uniprot Description

TAP1: a 'transporter associated with antigen processing' (TAP) protein. Member of the ATP binding cassette (ABC) family of transmembrane transporters. Also acts as a molecular scaffold for the final stage of MHC class I folding, namely the binding of peptide. Nascent MHC class I molecules associate with TAP via tapasin. Inhibited by the covalent attachment of herpes simplex virus ICP47 protein, which blocks the peptide-binding site of TAP. Inhibited by human cytomegalovirus US6 glycoprotein, which binds to the lumenal side of the TAP complex and inhibits peptide translocation by specifically blocking ATP-binding to TAP1 and prevents the conformational rearrangement of TAP induced by peptide binding. Inhibited by human adenovirus E3-19K glycoprotein, which binds the TAP complex and acts as a tapasin inhibitor, preventing MHC class I/TAP association. Expression of TAP1 is down-regulated by human Epstein-Barr virus vIL-10 protein, thereby affecting the transport of peptides into the endoplasmic reticulum and subsequent peptide loading by MHC class I molecules. Defects in TAP1 are a cause of bare lymphocyte syndrome.

Protein type: Membrane protein, integral; Transporter; Membrane protein, multi-pass

Chromosomal Location of Human Ortholog: 6p21.3

Cellular Component: endoplasmic reticulum membrane; TAP complex; membrane; mitochondrion; integral to membrane; integral to endoplasmic reticulum membrane

Molecular Function: protein binding; protein homodimerization activity; peptide transporter activity; TAP1 binding; peptide antigen binding; MHC class I protein binding; ATPase activity, coupled to transmembrane movement of substances; TAP2 binding; ADP binding; ATP binding; peptide-transporting ATPase activity

Biological Process: peptide transport; intracellular transport of viral proteins in host cell; antigen processing and presentation of peptide antigen via MHC class I; metabolic process; antigen processing and presentation of exogenous peptide antigen via MHC class I; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; defense response; antigen processing and presentation of endogenous peptide antigen via MHC class I; transmembrane transport; cytosol to ER transport

Disease: Bare Lymphocyte Syndrome, Type I